Endocrine orbitopathy: the present view of a clinical endocrinologist

• Published in: Vnitřní lékar̆stvĭ Vol. 63; no. 10; p. 690
• Main Author: Jiskra, Jan
• Format: Journal Article
• Language: Czech
• Published: Czech Republic 2017
• ISSN: 0042-773X
• DOI: 10.36290/vnl.2017.137

Graves orbitopathy (GO) occurs in 25-50 % cases of Graves disease. Only in 5 % of patients the eye threatening GO is present. About 5-10 % and 10 % cases are present in euthyroid and hypothyroid patients respectively. All patients with GO should be assessed for activity (clinical activity score - CAS) and severity of the disease. Basic preconditions of the treatment are maintenance of euthyroidism, an effort to stop smoking, and referring of patients with moderate to severe and sight threatening GO to specialized thyroid eye centers. The first line treatment includes maintenance of wet eye (lubricants), supplementation of selenium deficiency, intravenous glucocorticoids, radiotherapy and surgery. Cases with moderate to severe GO should be treated with intravenous glucocorticoids in thyroid eye centers, however, the risk/benefit ratio in all cases should be considered. Cases with sight threatening GO should be immediately referred to thyroid eye centers, high-dose intravenous glucocorticoids are administered, and when the clinical response is absent within 2 weeks, surgical orbital decompression is recommended. Other immunosuppressive drugs (cyclosporine, mycophenolate mofetil) or biological therapy (teprotumumab) are not routinely recommended because of lack of evidence obtained by randomized controlled trials.Key words: clinical activity score - dysthyroid optic neuropathy - Graves orbitopathy - intravenous glucocorticoids - mycophenolate mofetil.